CF
CAPR icon

Corebridge Financial’s Capricor Therapeutics CAPR Stock Holding History

Corebridge Financial’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,946
Closed -$170K – 463
2025
Q1 		$170K Sell
17,946
-266
-1% -$3.69K ﹤0.01% 2164
2024
Q4 		$251K Buy
18,212
+4,434
+32% +$77.7K ﹤0.01% 2040
2024
Q3 		$210K Buy
13,778
+122
+0.9% +$603 ﹤0.01% 2210
2024
Q2 		$65.3K Buy
+13,656
New +$76.1K ﹤0.01% 2811

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Corebridge Financial's CAPR Position: Q2 2025 in Review

Corebridge Financial sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 17,946 shares — an estimated $170K sold.

Corebridge Financial first reported a position in CAPR in Q2 2024 and held it in 4 quarters. The position peaked at $251K in Q4 2024. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • Corebridge Financial reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 17,946 Capricor Therapeutics shares in Q2 2025, an estimated $170K.
  • Corebridge Financial first reported a position in Capricor Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Capricor Therapeutics position peaked at $251K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.